DE60226334D1 - Neue antiphlogistische androstan derivate - 17-carboxy-lactone substituiert mit einer aryl-carboxylic estergruppe in der 17.alpha.-stelle - Google Patents
Neue antiphlogistische androstan derivate - 17-carboxy-lactone substituiert mit einer aryl-carboxylic estergruppe in der 17.alpha.-stelleInfo
- Publication number
- DE60226334D1 DE60226334D1 DE60226334T DE60226334T DE60226334D1 DE 60226334 D1 DE60226334 D1 DE 60226334D1 DE 60226334 T DE60226334 T DE 60226334T DE 60226334 T DE60226334 T DE 60226334T DE 60226334 D1 DE60226334 D1 DE 60226334D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- aryl
- alpha
- stelle
- antiphlogistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0125259 | 2001-10-20 | ||
GBGB0125259.2A GB0125259D0 (en) | 2001-10-20 | 2001-10-20 | Novel compounds |
PCT/EP2002/011634 WO2003035668A2 (en) | 2001-10-20 | 2002-10-17 | Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60226334D1 true DE60226334D1 (de) | 2008-06-12 |
DE60226334T2 DE60226334T2 (de) | 2009-06-04 |
Family
ID=9924247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60226334T Expired - Lifetime DE60226334T2 (de) | 2001-10-20 | 2002-10-17 | Neue antiphlogistische androstan derivate - 17-carboxy-lactone substituiert mit einer aryl-carboxylic estergruppe in der 17.alpha.-stelle |
Country Status (9)
Country | Link |
---|---|
US (1) | US7405206B2 (de) |
EP (1) | EP1444248B1 (de) |
JP (1) | JP4495456B2 (de) |
AT (1) | ATE393771T1 (de) |
AU (1) | AU2002350561A1 (de) |
DE (1) | DE60226334T2 (de) |
ES (1) | ES2304457T3 (de) |
GB (1) | GB0125259D0 (de) |
WO (1) | WO2003035668A2 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
EP1924553A1 (de) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylaminderivate und anwendungen davon |
AU2006303452B2 (en) | 2005-10-21 | 2011-06-09 | Novartis Ag | Human antibodies against IL13 and therapeutic uses |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
AR059216A1 (es) * | 2006-01-27 | 2008-03-19 | Sun Pharmaceutical Ind Ltd | 11b-hidroxiandrosta-4-eno-3-onas |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EP2322525B1 (de) | 2006-04-21 | 2013-09-18 | Novartis AG | Purinderivate als Adenosin A2A Rezeptoragonisten |
AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
DE602007011670D1 (de) | 2007-01-10 | 2011-02-10 | Irm Llc | Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer |
ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
PL2444120T3 (pl) | 2007-12-10 | 2018-02-28 | Novartis Ag | Spirocyklicze analogi amiloridu jako blokery ENac |
JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
MX2011007036A (es) | 2008-12-30 | 2011-07-20 | Pulmagen Therapeutics Inflammation Ltd | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios. |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
AR077101A1 (es) | 2009-06-16 | 2011-08-03 | Schering Corp | Esteroides de heteroarilo (3,2-c), como agonistas de receptor glucocorticoide, composiciones y usos de los mismos |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2673277A1 (de) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
PE20140378A1 (es) | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CN110507654A (zh) | 2012-04-03 | 2019-11-29 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
EP3007697B1 (de) | 2013-06-14 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1-inhibitoren zur induzierung von bronchodilatation |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
EA033571B1 (ru) | 2014-04-24 | 2019-11-06 | Novartis Ag | Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы |
CN106458979B (zh) | 2014-04-24 | 2020-03-27 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物 |
ES2761569T3 (es) | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
US20200383960A1 (en) | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
BR112022002569A2 (pt) | 2019-08-28 | 2022-07-19 | Novartis Ag | Derivados de 1,3-fenil heteroarila substituídos e seu uso no tratamento de doenças |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3828080A (en) | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
WO1997024365A1 (en) * | 1995-12-29 | 1997-07-10 | Glaxo Group Limited | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
EA005992B1 (ru) * | 2000-08-05 | 2005-08-25 | Глаксо Груп Лимитед | S-ФТОРМЕТИЛОВЫЙ ЭФИР 6α,9α-ДИФТОР-17α-[(2-ФУРАНИЛКАРБОНИЛ)ОКСИ]-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОКИСЛОТЫ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО АГЕНТА |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
EP1480996A1 (de) * | 2002-02-04 | 2004-12-01 | Glaxo Group Limited | Armorphes fluticason-2-furoat, pharmazeutische zusammensetzungen davon und deren umwandlung in die kristalline, nichtsolvatisierte form |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2001
- 2001-10-20 GB GBGB0125259.2A patent/GB0125259D0/en not_active Ceased
-
2002
- 2002-10-17 AT AT02785235T patent/ATE393771T1/de not_active IP Right Cessation
- 2002-10-17 AU AU2002350561A patent/AU2002350561A1/en not_active Abandoned
- 2002-10-17 EP EP02785235A patent/EP1444248B1/de not_active Expired - Lifetime
- 2002-10-17 JP JP2003538181A patent/JP4495456B2/ja not_active Expired - Lifetime
- 2002-10-17 WO PCT/EP2002/011634 patent/WO2003035668A2/en active IP Right Grant
- 2002-10-17 DE DE60226334T patent/DE60226334T2/de not_active Expired - Lifetime
- 2002-10-17 US US10/492,813 patent/US7405206B2/en not_active Expired - Lifetime
- 2002-10-17 ES ES02785235T patent/ES2304457T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4495456B2 (ja) | 2010-07-07 |
EP1444248A2 (de) | 2004-08-11 |
US7405206B2 (en) | 2008-07-29 |
JP2005509642A (ja) | 2005-04-14 |
EP1444248B1 (de) | 2008-04-30 |
WO2003035668A3 (en) | 2003-07-31 |
DE60226334T2 (de) | 2009-06-04 |
ATE393771T1 (de) | 2008-05-15 |
US20050054622A1 (en) | 2005-03-10 |
WO2003035668A2 (en) | 2003-05-01 |
ES2304457T3 (es) | 2008-10-16 |
AU2002350561A1 (en) | 2003-05-06 |
GB0125259D0 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60226334D1 (de) | Neue antiphlogistische androstan derivate - 17-carboxy-lactone substituiert mit einer aryl-carboxylic estergruppe in der 17.alpha.-stelle | |
EP2067784A3 (de) | 17.beta.-Carbothioat-17.alpha.-Arylcarbonyloxyloxy-Androstan-Derivate als entzündungshemmende Mittel | |
CY1110243T1 (el) | Ανταγωνιστες npyy5 | |
ID23666A (id) | Senyawa-senyawa kimia | |
YU49443B (sh) | Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija | |
IS6658A (is) | Ný efnasambönd | |
NO20022857D0 (no) | Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immune eller kardiovaskul¶re sykdommer | |
PT1263724E (pt) | Novos compostos | |
WO2003062259A3 (en) | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents | |
YU40997A (sh) | Novi oksadiazoli, postupci za njihovo pripremanje | |
MY129796A (en) | Novel anti-inflammatory androstane derivatives | |
FI970113A0 (fi) | Helico-bakteerin vastaisia atsolonien sulfonamidijohdannaisia | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
DE69828265D1 (de) | Zusatz zur herstellung von hochumformbarem mörtelzement | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
NO20040881L (no) | Orale antidiabetes midler. | |
SE9903997D0 (sv) | New compounds | |
SE0102055D0 (sv) | New Compounds | |
ATE297903T1 (de) | Substituierte phenyluracile | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
HRP20010630B1 (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists | |
ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate | |
HUP0004590A2 (hu) | Endotelin-antagonista imidazolszármazékokat és béta receptor blokkolókat tartalmazó kombinációs gyógyszerkészítmények | |
DE502004006869D1 (de) | alpha-(1' -HYDROXYALKYL)ACRYLATE ENTHALTENDE BESCHICHTUNGSMASSEN | |
DE69828390D1 (de) | Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |